Exabis Library
Welcome to the e-CCO Library!
P524: Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P524: Endoscopic dilations of intestinal stenosis in Crohn's disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P524: Long-term outcomes after restorative proctocolectomy and ileal pouch-anal anastomosis in children compared to adults
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P524: Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P524: Systematic review of calcineurin inhibitors (CNI) and vedolizumab (VDZ) combination therapy in acute severe ulcerative colitis (ASUC)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P525: A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P525: Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P525: Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of “real world data” from the UK
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P525: Patients' Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Diseases, Meir Medical Center, Kfar Saba, Israel
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P525: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P525: The benefits of anti-TNF drug and antidrug antibody (ADAb) level monitoring in a DGH
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P526: A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P526: A prospective 52-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's disease as detected by colon capsule endoscopy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P526: Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P526: Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P526: Social functioning, work-productivity and psychological assessment in a cohort of patients with inflammatory bowel disease: an observational study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P526: Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM